Cargando…

Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy

Introduction: The disease activity associated with the drug-utilization patterns of biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) is poorly investigated in real-world studies on rheumatoid arthritis (RA) patients. To investigate the relationship between biologic DMARD initiation/discontin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Convertino, Irma, Cazzato, Massimiliano, Tillati, Silvia, Giometto, Sabrina, Gini, Rosa, Valdiserra, Giulia, Cappello, Emiliano, Ferraro, Sara, Bonaso, Marco, Bartolini, Claudia, Paoletti, Olga, Lorenzoni, Valentina, Trieste, Leopoldo, Filippi, Matteo, Turchetti, Giuseppe, Cristofano, Michele, Blandizzi, Corrado, Mosca, Marta, Lucenteforte, Ersilia, Tuccori, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561246/ https://www.ncbi.nlm.nih.gov/pubmed/37818193 http://dx.doi.org/10.3389/fphar.2023.1244486

Ejemplares similares

Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study
por: Convertino, Irma, et al.
Publicado: (2021)

Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases
por: Convertino, Irma, et al.
Publicado: (2021)

Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis
por: Convertino, Irma, et al.
Publicado: (2023)

Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks
por: Giometto, Sabrina, et al.
Publicado: (2022)

The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance
por: Tuccori, Marco, et al.
Publicado: (2020)

Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients
por: Convertino, Irma, et al.
Publicado: (2020)

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
por: Tuccori, Marco, et al.
Publicado: (2020)

Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies
por: Ferraro, Sara, et al.
Publicado: (2019)

Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
por: TUFAN, Abdurrahman, et al.
Publicado: (2020)

Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation
por: TUFAN, Abdurrahman, et al.
Publicado: (2021)

Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents
por: Infante, Marco, et al.
Publicado: (2022)

Kinase inhibitors: a new class of antirheumatic drugs
por: Kyttaris, Vasileios C
Publicado: (2012)

Antirheumatic drugs and reproduction in women and men with chronic arthritis
por: Bazzani, Chiara, et al.
Publicado: (2015)

Old and new antirheumatic drugs for the treatment of COVID-19
por: Benucci, Maurizio, et al.
Publicado: (2020)

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
por: Lems, Willem, et al.
Publicado: (2021)

Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis
por: Piragine, Eugenia, et al.
Publicado: (2022)

Cost-effectiveness analysis and prevention effects of ultra-orphan drugs for rare diseases: an in silico model applied to Cryopyrin Associated Periodic Syndromes (CAPS)
por: Trieste, L, et al.
Publicado: (2015)

Anatomy of an extensively drug-resistant Klebsiella pneumoniae outbreak in Tuscany, Italy
por: Martin, Melissa J., et al.
Publicado: (2021)

Previous Humoral Immunity to the Endemic Seasonal Alphacoronaviruses NL63 and 229E Is Associated with Worse Clinical Outcome in COVID-19 and Suggests Original Antigenic Sin
por: Focosi, Daniele, et al.
Publicado: (2021)

Polytherapy and Multimorbidity Pattern of Users of Anti-VEGF Drugs and Dexamethasone for the Treatment of Age-Related Macular Degeneration and other Vascular Retinopathies in Clinical Practice
por: Lucenteforte, Ersilia, et al.
Publicado: (2023)

Molecular mechanisms of resistance to disease modifying antirheumatic drugs (DMARDs)
por: Jansen, G, et al.
Publicado: (2002)

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
por: Judge, Andy, et al.
Publicado: (2017)

Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists
por: Kawazoe, Mai, et al.
Publicado: (2021)

Adherence to Oral Antidiabetic Drugs in Patients with Type 2 Diabetes: Systematic Review and Meta-Analysis
por: Piragine, Eugenia, et al.
Publicado: (2023)

Sex differences in the utilization of drugs for COVID‐19 treatment among elderly residents in a sample of Italian nursing homes
por: Spini, Andrea, et al.
Publicado: (2022)

Tuscany Valley
por: Alexander, Philip
Publicado: (2022)

Are biologics more effective than classical disease-modifying antirheumatic drugs?
por: Nurmohamed, Michael T, et al.
Publicado: (2008)

Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs
por: Sokka, Tuulikki, et al.
Publicado: (2008)

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
por: Kemper, Alex R, et al.
Publicado: (2012)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Frequency and trends of disease‐modifying antirheumatic drug (DMARD) use in Germany
por: Fassmer, Alexander M., et al.
Publicado: (2016)

Immunodeficiency and autoimmunity during biological disease-modifying antirheumatic drug therapy
por: Czekalska, Anna, et al.
Publicado: (2019)

Rare diseases under different levels of economic analysis: current activities, challenges and perspectives
por: Cannizzo, Sara, et al.
Publicado: (2018)

Plasma Torquetenovirus (TTV) microRNAs and severity of COVID-19
por: Stincarelli, Maria Alfreda, et al.
Publicado: (2022)

Tuscany SCA in action
por: Laws, Simon
Publicado: (2011)

Acute portal vein thrombosis precipitated by indomethacin in a HCV-positive elderly patient
por: Mantarro, Stefania, et al.
Publicado: (2012)

Utilization Patterns of Disease-Modifying Antirheumatic Drugs in Elderly Rheumatoid Arthritis Patients
por: Jin, Xue-Mei, et al.
Publicado: (2014)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
por: Xia, Yunfei, et al.
Publicado: (2016)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
por: Kaló, Zoltán, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3h79hh4ar4j5db6nogtveaoern